(Q37103086)

English

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

scientific article published on December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

phase II clinical trial

0 references

0 references

metastatic breast cancer

1 reference

based on heuristic

inferred from title

9

object named as

Edith A Perez

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

4

object named as

Wilma L Lingle

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Alvaro Moreno-Aspitia

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Roscoe F Morton

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

David W Hillman

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Kendrith M Rowland

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Martin Wiesenfeld

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Patrick J Flynn

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Tom R Fitch

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

1 December 2008

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

27

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

11-15

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645094

14 September 2017

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645094

14 September 2017

Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645094

14 September 2017

Improving the design of phase II trials of cytostatic anticancer agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645094

14 September 2017

General and statistical hierarchy of appropriate biologic endpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645094

14 September 2017

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645094

14 September 2017

New strategies for managing metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645094

14 September 2017

Current management of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645094

14 September 2017

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645094

29 September 2017

Global trends in breast cancer incidence and mortality 1973-1997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645094

29 September 2017

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2645094

3 September 2018

Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047293

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2007.15.5242

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37103086&oldid=2134593305"